Cargando…

Case Report: CD19 and CD20 monoclonal antibodies with sequential chemotherapy for refractory acute B-lymphocytic leukemia in children

OBJECTIVE: This paper observes the efficacy of chemotherapy combined with CD19 and CD20 monoclonal antibodies in clearing minimal residual disease (MRD) and bridging transplantation for refractory acute B-lymphoblastic leukemia (B-ALL) in children and reviews the literature. METHODS: A 4-year-old bo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jia-Nan, Li, Yu, Lin, Ji-Xun, Wang, Li-Na, Zhang, Xiao-Li, Ouyang, Juan, Chen, Du-Bo, Chen, Shao-Qian, Li, Jun-Xun, Luo, Xue-Qun, Tang, Yan-Lai, Huang, Li-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690758/ https://www.ncbi.nlm.nih.gov/pubmed/38045698 http://dx.doi.org/10.3389/fimmu.2023.1280759

Ejemplares similares

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
por: Evans, Sarah S., et al.
Publicado: (2015)

CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells
por: Jiang, Shuang, et al.
Publicado: (2016)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
por: Liu, Sining, et al.
Publicado: (2023)

Possible role of CD22, CD79b and CD20 expression in distinguishing small lymphocytic lymphoma from chronic lymphocytic leukemia
por: Jovanovic, Danijela, et al.
Publicado: (2014)

Response to: Monoclonal antibodies targeting CD20
por: Klein, Christian, et al.
Publicado: (2013)

Anti-CD20 monoclonal antibody combined with adenovirus vector-mediated IL-10 regulates spleen CD4(+)/CD8(+) T cells and T-bet/GATA-3 expression in NOD mice
por: Tang, Aiping, et al.
Publicado: (2017)

Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity
por: Zhang, Na, et al.
Publicado: (2022)

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
por: Steinhardt, Maximilian Johannes, et al.
Publicado: (2020)

Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis
por: Nguyen, Thi Thuy, et al.
Publicado: (2023)

Phase I Study of Ofatumumab, a Human Anti-CD20 Antibody, in Japanese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
por: Ogura, Michinori, et al.
Publicado: (2013)

Novel CD20 monoclonal antibodies for lymphoma therapy
por: Cang, Shundong, et al.
Publicado: (2012)

A novel glycosylated anti-CD20 monoclonal antibody from transgenic cattle
por: Zhang, Ran, et al.
Publicado: (2018)

Abnormal numbers of CD4(+) T lymphocytes and abnormal expression of CD4(+) T lymphocyte-secreted cytokines in patients with immune-related haemocytopenia
por: Chen, Jin, et al.
Publicado: (2019)

Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy
por: Chen, Wei, et al.
Publicado: (2021)

A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia
por: Li, Yi, et al.
Publicado: (2021)

Monoclonal antibodies binding to different epitopes of CD20 differentially sensitize DLBCL to different classes of chemotherapy
por: Lee, Brian, et al.
Publicado: (2023)

Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript
por: Voruz, Sophie, et al.
Publicado: (2021)

Ofatumumab: a novel monoclonal anti-CD20 antibody
por: Lin, Thomas S
Publicado: (2010)

Anti-CD20 monoclonal antibodies: reviewing a revolution
por: Casan, J. M. L., et al.
Publicado: (2018)

Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
por: Yin, Yuzhen, et al.
Publicado: (2022)

Activation of rat T lymphocytes by anti-CD2 monoclonal antibodies
Publicado: (1988)

Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma
por: Chen, Fei, et al.
Publicado: (2015)

A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy
por: Zhang, Yu, et al.
Publicado: (2022)

Adriamycin‐loaded exosome with anti‐CD20 aptamers selectively suppresses human CD20+ melanoma stem cells
por: Chen, Hairong, et al.
Publicado: (2022)

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
por: Zhang, Li-Na, et al.
Publicado: (2018)

CD73 Promotes Chronic Lymphocytic Leukemia
por: Allard, David, et al.
Publicado: (2022)

Reduced frequency and functional defects of CD4(+)CD25(high)CD127(low/−) regulatory T cells in patients with unexplained recurrent spontaneous abortion
por: Luo, Li, et al.
Publicado: (2020)

Surgical treatment of refractory epilepsy after chemotherapy in two children with leukemia()
por: Leng, Yun, et al.
Publicado: (2013)

Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
por: Luo, Chengxin, et al.
Publicado: (2021)

Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
por: Delgado, Raquel, et al.
Publicado: (2021)

Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia
por: Miao, Yi, et al.
Publicado: (2016)

T-cell large granular lymphocytic (LGL) leukemia consists of CD4(+)/CD8(dim) and CD4(-)/CD8(+) LGL populations in association with immune thrombocytopenia, autoimmune neutropenia, and monoclonal B-cell lymphocytosis
por: Kuwahara, Naoya, et al.
Publicado: (2019)

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
por: Gui, Lin, et al.
Publicado: (2016)

Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response
por: Singh, Vijay, et al.
Publicado: (2015)

Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody, in the Treatment of Severe Refractory Anti-N-methyl-D-Aspartate Receptor Encephalitis: Two Case Reports
por: Xue, Hongfei, et al.
Publicado: (2023)

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
por: Danilov, Alexey V., et al.
Publicado: (2021)

Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis
por: Saidha, Shiv, et al.
Publicado: (2023)

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
por: Yan, Lingzhi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ucvjef51ebi6jinkri1ms6jgcg